Search results
San Diego COVID-19 test maker Cue Health — once worth $2.3B — lays off entire company and shuts down
U-T San Diego· 13 hours agoCOVID-19 test kits to the NBA and Google, is laying off all employees and shutting down on Friday....
Mainers, you might have unclaimed pandemic-era relief money. Here's how to check.
WCSH 6 Portland· 2 days agoGov. Janet Mills and State Treasurer Henry Beck said approximately 40,000 unclaimed relief payments...
Counties receiving the most small business loans in Ohio
WCMH via Yahoo Finance· 4 days agoThe Small Business Administration backed loans worth $27.5 billion through its primary lending...
Federal Spending Rescued Mass Transit During Covid. What Happens Now?
New York Times· 38 minutes agoThe government provided $69.5 billion in relief funds to help keep transit on track during Covid-19....
Former Montgomery County restaurant owner indicted for almost $1M in alleged PPP and RRF fraud -...
The Business Journals· 5 days agoGiuseppina "Josephine" Leone of North Wales is...for the Eastern District of Pennsylvania announced....
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 6 days agoNot only does this investment include funds received from their COVID-19 American Rescue Plan (ARP) law but also other...Strengthening HBCUs and student ...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 4 days agoNearly 900 undergraduates of the Class of 2024 celebrated their send-off from Bentley University in a very different way than their 2020 arrival amid the COVID-19& ...
Doing What’s Right
KGTV San Diego· 2 days agoKeep track of the way people are spending your tax dollars and treating your community.
Biden’s Student Loan Forgiveness Efforts Don’t Go Far Enough, the Debt Collective Says
Teen Vogue via Yahoo Finance· 5 days agoIOU is a series exploring the impact of the student debt crisis on the day-to-day lives of young...
FDA Approves Tarlatamab for Extensive-Stage SCLC
Medscape· 6 days agoContinued approval of the first-in-class bispecific T-cell engager (BiTE) may depend on proof of clinical benefit.